Kesimpta was approved in August 2020 as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing ...

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator.

Novartis on Friday posted quarterly adjusted net income well above analyst estimates on forecast-beating sales of established ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of $1.98 per ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...

Briumvi, a B-cell therapy for MS, faces competition from subcutaneous alternatives like Kesimpta; TG aims to initiate a pivotal program by mid-2025. Financially, TG Therapeutics is stable with a ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

European shares closed at a record high on Friday (Jan 31), led by technology stocks, as earnings from companies such as ...